Analytical Data
-
Gene name
PD-1
- Application
-
Alternative Names
CD279; PDCD1; SLEB2; HPD1P
-
Species
Cat
-
Source
HEK293
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
A9YUA6
-
Expression Region
Pro31~Thr143
-
Molecular Weight
22-30kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Programmed cell death protein 1 (PD-1) is an immune checkpoint receptor that plays a crucial role in regulating immune responses, particularly in maintaining self-tolerance and inhibiting autoimmunity. Discovered in the late 1990s, PD-1 functions by binding to its ligands, PD-L1 and PD-L2, which are often upregulated in tumor tissues, leading to the downregulation of T-cell activity and promoting tumor immune evasion. Research has shown that blocking the PD-1 pathway can enhance the immune system's ability to recognize and destroy cancer cells, paving the way for the development of immune checkpoint inhibitors, a revolutionary class of cancer therapies. The creation of recombinant PD-1 proteins has facilitated the study of its structure, function, and interactions at a molecular level, providing insights into the mechanisms underlying immune regulation. This research advances our understanding of PD-1's role in oncology and autoimmune diseases, contributing to the development of novel therapeutic strategies aimed at improving patient outcomes through immune modulation. As PD-1-targeting therapies have shown promising clinical results, ongoing research continues to explore its applications, potential combinations with other treatments, and the optimization of its efficacy in various malignancies.
